Alethia Young
Stock Analyst at Cantor Fitzgerald
(3.68)
# 772
Out of 4,918 analysts
141
Total ratings
54.46%
Success rate
30.69%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $9.16 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $15.93 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $558.87 | +52.09% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $0.52 | +3,374.23% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.63 | +3,580.98% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $3.38 | +166.27% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $6.08 | +459.21% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $131.95 | +147.82% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $2.34 | +1,182.05% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $10.49 | +5,314.68% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $462.13 | -39.19% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.72 | +115.05% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.07 | +9,058.88% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $296.88 | -0.63% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $113.18 | -24.01% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $35.02 | +37.06% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.11 | +269.91% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $35.05 | +105.42% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.33 | +275.94% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $75.59 | +32.29% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $174.48 | +15.20% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $52.13 | +63.05% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $10.49 | +205.05% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $15.91 | +1,263.92% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $24.67 | +94.57% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $15.14 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $401.80 | -61.67% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $58.14 | +99.52% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $3.07 | +3,352.77% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $11.49 | +143.69% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $203.49 | -59.70% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $294.28 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.12 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.16
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.93
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $558.87
Upside: +52.09%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.52
Upside: +3,374.23%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.63
Upside: +3,580.98%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $3.38
Upside: +166.27%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $6.08
Upside: +459.21%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $131.95
Upside: +147.82%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $2.34
Upside: +1,182.05%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $10.49
Upside: +5,314.68%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $462.13
Upside: -39.19%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $3.72
Upside: +115.05%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.07
Upside: +9,058.88%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $296.88
Upside: -0.63%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $113.18
Upside: -24.01%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $35.02
Upside: +37.06%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $8.11
Upside: +269.91%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $35.05
Upside: +105.42%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.33
Upside: +275.94%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $75.59
Upside: +32.29%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $174.48
Upside: +15.20%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $52.13
Upside: +63.05%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $10.49
Upside: +205.05%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $15.91
Upside: +1,263.92%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $24.67
Upside: +94.57%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $15.14
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $401.80
Upside: -61.67%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $58.14
Upside: +99.52%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $3.07
Upside: +3,352.77%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $11.49
Upside: +143.69%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $203.49
Upside: -59.70%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $294.28
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.12
Upside: -